PSMA‐heterogeneity in metastatic castration‐resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy

Author:

Derlin Thorsten1ORCID,Riethdorf Sabine2,Schumacher Udo34,Lafos Marcel5,Peine Sven6,Coith Cornelia2,Ross Tobias L.1,Pantel Klaus2,Bengel Frank M.1

Affiliation:

1. Department of Nuclear Medicine Hannover Medical School Hannover Germany

2. University Medical Center Hamburg‐Eppendorf Institute of Tumor Biology Hamburg Germany

3. Department of Anatomy and Experimental Morphology University Medical Center Hamburg‐Eppendorf Hamburg Germany

4. Medical School Berlin Berlin Germany

5. Hannover Medical School Institute of Pathology Hannover Germany

6. University Medical Center Hamburg‐Eppendorf Institute of Transfusion Medicine Hamburg Germany

Abstract

AbstractBackgroundWe explored the interrelation between prostate‐specific membrane antigen (PSMA) expression on circulating tumor cells (CTCs) and that of solid metastatic lesions as determined by whole‐body PSMA‐targeted positron emission tomography (PET) to refine the prediction of response to subsequent PSMA‐targeted radioligand therapy (RLT).MethodsA prospective study was performed in 20 patients with advanced mCRPC. Of these, 16 underwent subsequent RLT with [177Lu]Lu‐PSMA‐617 at a dose of 7.4 GBq every 6–8 weeks. PSMA expression on CTCs using the CellSearch system was compared to clinical and serological results, and to marker expression in targeted imaging and available histological sections of prostatectomy specimens (19% of RLT patients). Clinical outcome was obtained after two cycles of RLT.ResultsMarked heterogeneity of PSMA expression was observed already at first diagnosis in available histological specimens. Targeted whole‐body imaging also showed heterogeneous inter‐ and intra‐patient PSMA expression between metastases. Heterogeneity of CTC PSMA expression was partially paralleled by heterogeneity of whole‐body tumor burden PSMA expression. Twenty percent of CTC samples showed no PSMA expression, despite unequivocal PSMA expression of solid metastases at PET. A high fraction of PSMA‐negative CTCs emerged as the sole predictor of poor RLT response (odds ratio [OR]: 0.9379 [95% confidence interval, CI, 0.8558–0.9902]; p = 0.0160), and was prognostic for both shorter progression‐free survival (OR: 1.236 [95% CI, 1.035–2.587]; p = 0.0043) and overall survival (OR: 1.056 [95% CI, 1.008–1.141]; p = 0.0182).ConclusionThis proof‐of‐principle study suggests that liquid biopsy for CTC PSMA expression is complementary to PET for individual PSMA phenotyping of mCRPC.

Funder

European Research Council

Movember Foundation

Publisher

Wiley

Subject

Urology,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3